|Bid||42.98 x 1100|
|Ask||43.02 x 1100|
|Day's range||41.78 - 43.33|
|52-week range||28.39 - 90.20|
|Beta (5Y monthly)||0.97|
|PE ratio (TTM)||N/A|
|Earnings date||06 Dec 2021 - 10 Dec 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||40.46|
AUSTIN, Texas, September 28, 2021--Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Company has strengthened its leadership team with the appointments of Mark S. Berger, M.D. to the newly-created position of Chief Medical Officer and Hemant Kumar, Ph.D., CPM, EMBA to the newly-created position of Chief Manufacturing and Technology Officer.
Solar stocks have emerged as some of the worst-hit among the many sectors feeling the heat from growing contagion fears as the Evergrande crisis continues to unfold
Ladies and gentlemen, thank you for standing by for JinkoSolar Holding Company Limited's second-quarter 2021 earnings conference call. Thank you, everyone, for joining us today for JinkoSolar's second-quarter 2021 earnings conference call.